ATTO

Attovia Therapeutics, Inc.
CAPPED RATING

Attovia Therapeutics, Inc. (ATTO) is rated D (1.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
1.5 / 5.0
D
Value
D-
Factor Score 0.8 / 5.0
Growth
D
Factor Score 1.5 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.2
EV / EBITDA -11.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -36.6%
Price Return 12M -32.7%
Catalyst Signal 0.00
Market Cap $673.1M
TTM Revenue $1.8M
Price / Sales 374.0
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 D- (0.8) D (1.5) D- (0.8) D+ (1.5) C+ (2.6) D (1.5)
2026-11-10 F (0.6) D+ (1.6) D- (0.8) C (2.2) C+ (2.6) D+ (1.6)
2026-11-03 D- (0.8) D+ (1.6) D- (0.8) C- (1.9) C+ (2.7) D+ (1.5)
2026-10-27 D- (1.0) D+ (1.5) D- (0.8) D+ (1.7) C+ (2.6) D+ (1.5)
2026-10-20 D- (1.1) D+ (1.5) D- (0.8) C- (2.1) C+ (2.6) D+ (1.6)
Page 1 of 3